Compare Berkshire Hathaway Inc Class B (BRK.B) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Crispr Therapeutics AG — how do they compare? Berkshire Hathaway Inc Class B trades at $491.24, while Crispr Therapeutics AG trades at $50.54 (market cap $4.97B). The key difference: Berkshire Hathaway Inc Class B is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| BRK.B | CRSP | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $513.70 | $76.78 |
52-Week Low | $459.10 | $44.34 |
Market Cap | — | $4.97B |
Enterprise Value | — | $3.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Berkshire Hathaway Class B shares (BRK.B) trade at $496.79, up 0.63% on the day, with a bullish technical signal from moving averages. Analyst consensus is positive with 57% buy ratings. The stock's current price is near the pivot point of $497, with immediate resistance at $500 and support at $494.
The outlook remains favorable given strong institutional confidence and the company's diversified holdings, though risks include market volatility and economic cycles. Upside potential exists if the stock breaks above $500 resistance, supported by bullish momentum indicators.
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
